AMAG Seeks Feraheme Label Expansion - Analyst Blog

By
A A A

AMAG Pharmaceuticals ( AMAG ) recently submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for the intravenous (IV) dose of Feraheme (ferumoxytol). AMAG is looking to expand Feraheme's label as a treatment for anemia in adults suffering from iron deficiency anemia (IDA) with a history of unsuccessful oral iron therapy.

AMAG's sNDA submission was based on data from two phase III clinical trials (IDA-301 and IDA-302) which evaluated the use of Feraheme in adults suffering from IDA. Both the studies were successful in achieving their primary objective of meaningful improvements in hemoglobin from baseline.

We note that Feraheme is already approved in the US as an IV iron therapy to treat IDA in adults suffering from chronic kidney disease (CKD). In November this year, AMAG's European partner Takeda Pharmaceutical Company Limited ( TKPYY ) launched the drug for the same indication in the EU under the trade name, Rienso. Rienso is also approved and launched in Canada where it is also marketed by Takeda.

AMAG recorded third quarter 2012 Feraheme sales of $16.2 million. The company expects 2012 Feraheme revenue in the range of $58-$60 million.

Our Recommendation

We believe that successful label expansion of the drug will drive revenue further. We expect investor focus to remain on Feraheme's performance in the US as well as the EU.

We currently have an Outperform recommendation on the stock, which carries a Zacks #2 Rank (Buy). Other stocks in the pharma sector that carry a Zacks #1 (Strong Buy) Rank are Targacept ( TRGT ) and Repligen ( RGEN ).



AMAG PHARMA INC (AMAG): Free Stock Analysis Report

REPLIGEN (RGEN): Free Stock Analysis Report


(TKPYY): ETF Research Reports

TARGACEPT INC (TRGT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: AMAG , IDA , RGEN , TKPYY , TRGT

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

45,543,019
  • $16.75 ▲ 0.12%
44,349,390
  • $132.54 ▲ 0.88%
32,695,176
  • $3.01 ▲ 19.92%
28,073,679
  • $34.76 ▲ 2.75%
27,339,999
  • $9.15 ▼ 3.58%
26,142,754
  • $34.71 ▼ 1.03%
25,357,890
  • $46.90 ▼ 1.10%
24,562,443
  • $15.27 ▼ 1.55%
As of 5/22/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com